1. Medtech Insight
  2. >>Policy & Regulation
  3. >>Legal & IP

Supreme Court Health Reform Oral Arguments Leave Open Questions

Device firms should not stop preparing for the 2.3% excise tax, scheduled to take effect next January. Still, justices during oral arguments March 26-28 did not take off the table the prospect of ruling the entire health care reform legislation void.

It remains uncertain after oral arguments before the Supreme Court last week whether a series of non-insurance-related provisions in the 2010 Affordable Care Act will stay if the law’s individual mandate is deemed unconstitutional.

Device firms certainly should not stop making preparations for the 2.3% excise tax, scheduled to take effect next January, analysts...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

More from Policy & Regulation

Innovative Wants Injunction Against J&J Subsidiary After $442M Antitrust Verdict

 
• By Elizabeth Orr

Innovative Healthcare is asking for a permanent injunction against Johnson & Johnson subsidiary Biosense Webster after winning a $442 million antitrust verdict. The injunction aims to prevent continued anticompetitive practices in the electrophysiology catheter market.

MHRA’s Tallon Hails PMS Regulation As Start Of UK Device Framework Transformation

 
• By Ashley Yeo

16 June marked the first major new regulatory instrument in the UK’s post-Brexit transition to a standalone device regulatory system for Great Britain.

Increasing Safety Concerns Spur Scrutiny of Device Plastics Use

 
• By Elizabeth Orr

With new regulations limiting the use of plastics popping up worldwide, the medtech industry sees arguments on both sides. Some argue hasty bans of PFAS ("forever chemicals") would harm patients, while others say phthalates should be phased out to protect the public.